Aims: To describe the characteristics, treatment, and mortality in patients with ST-elevation myocardial infarction (STEMI) by use of chronic oral anticoagulant (OAC) therapy. Methods: Using data from the Global Registry of Acute Coronary Syndromes (GRACE), patient characteristics, treatment, and reperfusion strategies of STEMI patients on chronic OAC are described, and relevant variables compared with patients not on chronic OAC. Six-month post-discharge mortality rates were evaluated by Cox proportional hazard models. Results: Of 19,094 patients with STEMI, 574 (3.0%) were on chronic OAC at admission. Compared with OAC nonusers, OAC users were older (mean age 73 vs. 65 years), more likely to be female (37 vs. 29%), were more likely to have a history of atrial fibrillation, prosthetic heart valve, venous thromboembolism, or stroke/transient ischaemic attack, had a higher mean GRACE risk score (166 vs. 145), were less likely to be Killip class I (68 vs. 82%), and were less likely to undergo catheterization/percutaneous coronary intervention (52 vs. 66%, respectively). Of the patients who underwent catheterization, fewer OAC users had the procedure done within 24 h of admission (56.5 vs. 64.5% of OAC non-users). In propensity-matched analyses (n=606), rates of in-hospital major bleeding and in-hospital and 6-month post-discharge mortality were similar for OAC users and OAC non-users (2.7 and 3. 7%, p=0.64; 15 and 13%, p=0.56; 15 and 12%, p=0.47, respectively), rates of in-hospital recurrent myocardial infarction (8.6 and 2.0%, p<0.001) and atrial fibrillation (32 and 22%, p=0.004) were higher in OAC patients, and rates of 6-month stroke were lower (0.6 and 4.3%, p=0.038). Patients in both groups who underwent catheterization had lower mortality than those who did not undergo catheterization. Conclusions: This is the largest study to describe the characteristics and treatment of STEMI patients on chronic OAC. The findings suggest that patients on chronic OAC are less likely to receive guideline-indicated management, but have similar adjusted rates of in-hospital and 6-month mortality.
Introduction
The management of patients on chronic oral anticoagulation (OAC) who develop ST-segment elevation myocardial infarction (STEMI) presents a clinical conundrum. Many clinicians withhold or delay effective reperfusion and antithrombotic or antiplatelet therapies because of concerns over a potentially higher risk of bleeding among these patients.
Little is known about the best treatment strategy in this subset of patients when they present acutely. No randomized trials have addressed this question, and guidelines limit their comments on patients on OAC who present with STEMI to statements of caution due to a potentially increased bleeding risk. [1] [2] [3] The goal of this study was to describe the characteristics, treatments (reperfusion and associated therapies), and in-hospital and 6-month mortality rates in patients on chronic OAC and presenting with STEMI using data from the Global Registry of Acute Coronary Events (GRACE) and to compare them with patients not on chronic OAC.
Methods

Patients
GRACE was a prospective, multinational, observational registry in patients hospitalized for an acute coronary event (www.outcomes.org/grace). The design and methods have been published previously. 4 Briefly, GRACE included 70,359 patients admitted to 126 hospitals in 14 countries between 1999 and 2007. GRACE was designed to reflect a population representative of patients with acute coronary syndromes (ACS), irrespective of geographical region. Patients entered into the registry had to be ≥18 years old, alive at the time of hospital presentation, admitted with a presumptive diagnosis of ACS, and have one or more of the following: electrocardiographic changes consistent with ACS, serial increases in serum biochemical markers of cardiac necrosis, and documentation of coronary artery disease. The qualifying ACS must not have been precipitated by a significant non-cardiovascular comorbidity such as trauma or surgery. Patients were followed up for approximately 6 months after hospital discharge. The population for this study included 19,094 patients with STEMI, 574 of whom were receiving OAC at the time of hospital admission. Where required, study investigators received approval from their local hospital ethics or institutional review board for the conduct of the study.
Definitions
To characterize the onset of a myocardial infarction (MI) as a hospital outcome, it had to have occurred >24 h after hospital presentation, to have been confirmed by electrocardiographic changes or elevation of cardiac biomarkers, and to have involved one of the following scenarios: (a) patients with an admission diagnosis of unstable angina who developed an MI; (b) patients who were diagnosed with an MI after coronary artery bypass graft surgery (CABG) or a percutaneous coronary intervention (PCI) provided they had qualified for enrolment before the CABG or PCI; or (c) patients who had presented with an MI and were diagnosed as having had recurrent MI.
Patients receiving chronic OAC were defined as those routinely taking a vitamin K antagonist at home and within 7 days of hospital presentation.
All patients in whom cardiac catheterization was performed were included in the catheterization and/or PCI (Cath/PCI) group, regardless of whether a PCI was performed. Hours to Cath/PCI was defined as the time to the earliest procedure. The medical therapy group was defined as those who did not undergo Cath/PCI. Major bleeding in hospital had to be life threatening, require a transfusion of ≥2 units of packed red cells, cause a ≥10% decrease in haematocrit, or result in death. Six-month mortality encompassed all deaths occurring during the 180 days from the time of discharge from hospital.
Statistical methods
Data are presented as frequencies and percentages for categorical data, and as means and standard deviations (SD) for continuous variables. p-values are for Fisher's Exact test for binomial variables and the Wilcoxon rank-sum test for continuous variables. All tests were two-sided with α = 0.05. All analyses were performed using SAS software version 9.1 (SAS Institute, Cary, NC, USA).
To determine whether there was a relationship between time to Cath/PCI and 6-month mortality in STEMI patients on chronic OAC, Cox proportional hazard models were used, unadjusted and adjusted for other factors potentially associated with death. Candidate variables for adjustment included the GRACE risk score; 5 age; sex; new ST-segment elevation or left bundle branch block after the initial electrocardiogram; country; medical history of congestive heart failure (CHF), hypertension, peripheral artery disease, CABG, transient ischaemic attack (TIA) or stroke, atrial fibrillation, bleeding, coronary artery disease, MI, angina, or renal insufficiency; and chronic use of aspirin, thienopyridine, oral beta-blockers, diuretics, or amiodarone. After step-wise regression, the following significant (p<0.05) variables were retained in the model: GRACE risk score, medical history of CHF, and recurrent ST-segment elevation or new left bundle branch block. Complete covariate data were available for 472 patients. Cath/PCI was included in the model as a time-varying covariate to account for the fact that the patient's Cath/PCI status could change during hospitalization.
The proportional hazards assumption was checked for all variables using a covariate-by-time interaction, which was violated (p≤0.05) for time to Cath/PCI, meaning that the effect of Cath/PCI on death changed according to when the Cath/PCI was performed. The time of Cath/PCI was therefore classified into several categories for comparison with those not receiving Cath/PCI. Propensity-matched analyses. Propensity matching was performed to compare event rates in OAC users and nonusers. Multiple logistic regressions were done on a model whose outcome was OAC use or non-use, considering as covariates patient characteristics that showed the greatest difference between the two groups. One-to-one matching of OAC to non-OAC users was done, as the latter had a low probability of receiving OAC and thus had no OAC counterpart, whereas most OAC patients had at least one non-OAC counterpart. The probability of each matched pair's OAC use differed at most by 0.01.
Results
Patient population
Of the overall GRACE population 19,094 patients presented with STEMI, 574 (3.0%) of whom were OAC users.
Patients' baseline characteristics are shown in Table 1 . OAC users were significantly older and more likely to be female. Rates of atrial fibrillation, prosthetic heart valves, history of stroke/TIA, and history of MI were significantly higher among OAC users, whereas smoking was significantly more frequent among OAC non-users. There was no difference in history of major bleeding.
OAC users had an overall worse Killip class and a higher GRACE risk score compared with OAC non-users ( Table  2 ). Nearly one-third of patients on OAC were in the highest GRACE risk category compared with 16.0% of OAC non-users.
Medications
At admission, OAC users were more likely than OAC nonusers to be taking beta-blockers, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ ARB), and statins, whereas aspirin and thienopyridine use was similar in both groups ( Table 3) .
During hospitalization, fewer of the OAC users received aspirin, beta-blockers, statins, or thienopyridines compared with OAC non-users (Table 3 ). Vitamin K antagonist therapy was maintained in 52.4% of OAC Figure 1A . At discharge from hospital, OAC non-users were most likely to be given aspirin and thienopyridines (52.8%) or aspirin alone (36.3%), whereas medical therapy for OAC users was more varied (Figure 1B ).
Interventions and clinical outcomes
The rate of Cath/PCI during hospitalization was lower among OAC users than among OAC non-users (Table 4 ). Of the patients who had a Cath/PCI, just over half of the OAC users had the procedure performed in the first 24 h compared with almost two-thirds of OAC non-users.
Data were available for propensity matching in 319 patients because the strongest covariates associated with chronic OAC use were available only in the most recent version of the case report form. Non-OAC counterparts with similar model probabilities were found for 303 of these patients. In multiple logistic regression, the three strongest factors associated with chronic OAC use were medical history of atrial fibrillation, venous thromboembolism, and prosthetic valve replacement; other factors included age, presentation in Killip class III, and medical history of transient ischaemic attack, congestive heart failure, percutaneous coronary intervention, coronary artery bypass graft, and diabetes mellitus. The model c-statistic was 0.92.
After propensity matching, the three strongest factors in univariate analysis were similar among OAC users and non-users: 55.1% of OAC users and 55.7% of non-users had a history of atrial fibrillation; 6.3 and 3.6% had a prosthetic valve replacement; and 11.2 and 12.2% had a history of venous thromboembolism (full data not shown). In propensity-matched analyses, there was no significant difference in the overall frequency of in-hospital major bleeding in OAC users and non-users (Table 5) , while recurrent MI and atrial fibrillation occurred more frequently in OAC users. Unadjusted in-hospital mortality rates were higher Table 5 ). Among discharged patients, OAC users had a higher unadjusted mortality rate at 6 months than non-users (13.4 vs. 4.3%, p<0.0001; data not shown), whereas propensity-adjusted differences were not statistically significant (14.7 vs. 11.8%, p=0.47; Table  5 ). Adjusted 6-month stroke rates were lower in OAC users ( Table 5 ). No other adjusted differences were found.
Impact of Cath/PCI in OAC users
OAC users who underwent Cath/PCI during hospitalization were significantly younger, more likely to be male, to be in Killip class I, and have a lower GRACE risk score than OAC users who were treated with medical therapy only, whereas history of CABG did not differ between the two groups ( Table 6 ).
Major bleeding occurred at a higher rate in OAC users who had Cath/PCI compared to those treated medically, but hospital mortality was higher for patients treated medically. Among patients discharged alive from hospital, 20.0% of medically treated patients died within 6 months compared with 6.9% of those who underwent Cath/PCI ( Table 6 ).
Impact of timing of catheterization and use of OAC
The unadjusted Cox model suggested a survival advantage among OAC users undergoing Cath/PCI within 12 h of admission compared with those not undergoing Cath/PCI (Figure 2A) . However, the adjusted Cox model did not reveal a significant difference between the Cath/PCI and medical therapy groups regardless of the timing of the Cath/PCI (Figure 2A) .
Among OAC non-users, unadjusted and adjusted 6-month mortality was significantly lower among patients undergoing Cath/PCI within 12 h compared with no Cath/ PCI ( Figure 2B ).
Discussion
This study describes the clinical and treatment characteristics of patients on chronic OAC presenting with STEMI, as evaluated in the GRACE registry. Overall, these patients appeared to be less likely to undergo Cath/PCI, to receive antiplatelet and antithrombotic medications, or to receive other evidence-based therapies compared with STEMI patients not on chronic OAC.
Previous studies have highlighted the importance of preexisting conditions (e.g. valvular disease and cerebrovascular events) in the treatment selection and outcomes of patients presenting with an ACS. 6, 7 The use of OAC has been associated with adverse in-hospital events in the non-ST-elevation ACS population. In another GRACE study, patients on chronic OAC were found to have a 6% higher in-hospital adverse event rate than patients not on OAC. 8 In the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association guidelines (CRUSADE) Registry, non-STsegment elevation ACS patients on OAC at admission (n=7201) were less likely to receive antiplatelet and antithrombotic medications than patients not on OAC (n=93,877). 9 Furthermore, patients on chronic OAC were less likely to undergo diagnostic cardiac catheterization, PCI, or CABG, and waiting times for these procedures were longer. 9 Likewise, the RICO Survey of 2112 STEMI patients showed that the 93 patients on OAC were less likely to undergo reperfusion therapy or receive antiplatelet agents than patients not on OAC, and they experienced a higher incidence of in-hospital death, recurrent MI, and bleeding. 10 Our study shows similar results among the STEMI population. We found that STEMI patients on chronic OAC were also less likely to undergo reperfusion and that, when this was performed, it was seldom within the recommended times.
Choice of reperfusion therapy
An analysis of data from GRACE found that the use of evidence-based therapies and PCI has increased over time in the STEMI population, and this has been matched with statistically significant decreases in the rates of death, cardiogenic shock, and heart failure compared to fibrinolysis. 11 A concern specific to emergency PCI is that of access-site bleeding complications, particularly among patients receiving OAC. We found a significantly higher frequency of major bleeding among patients who underwent cardiac catheterization, but whether this was directly related to the degree of anticoagulation (international normalized ratio, INR) or to the more frequent of use of anticoagulant and antiplatelet therapies in the Cath/PCI group is not known. Overcoagulation is likely to have occurred and may explain these findings.
We analysed the data for either diagnostic catheterization or catheterization followed by a PCI assuming an intention to perform a PCI, because in real life, not all patients who present with STEMI have a coronary anatomy suitable for this procedure. We wanted to emphasize this principle in a challenging population, in which comorbidities and the administration of chronic OAC may have played a significant role in deciding who should undergo Cath/PCI and when it should be performed.
Choice of adjunctive pharmacotherapy and cardiac catheterization access site
With regard to adjunctive pharmacotherapies (e.g. aspirin, thienopyridines, glycoprotein IIb/IIIa inhibitors, heparins, and direct thrombin inhibitors) in OAC patients presenting with STEMI, there is no evidence to suggest that one drug is better or safer than another because these patients have traditionally been excluded from clinical trials involving such treatments ( Table 7) . Neither do we know whether different loading or maintenance doses of these drugs should be used.
The same applies to the choice of access site for cardiac catheterization. Two recent trials provide evidence that transradial catheterization is associated with a lower bleeding risk, but they too excluded patients on OAC. 16, 24 It would appear reasonable, however, to infer that patients on OAC should preferably undergo transradial catheterization.
In the absence of evidence, the use of anticoagulation in the cardiac catheterization laboratory varies widely for OAC patients with STEMI: while some operators may choose the direct thrombin inhibitor bivalirudin because of its overall lower bleeding risk, others elect to use unfractionated heparin because its effects can be reversed with protamine in the event that bleeding occurs.
Discharge medications and outcomes
Another central problem is the systematic definition of a discharge medication plan for patients who require single or dual antiplatelet therapy in addition to OAC due to their long-term bleeding risk. These patients are treated with great variability. Various retrospective and prospective studies have addressed the role of triple therapy (aspirin plus thienopyridine plus vitamin K antagonist) and bleeding risk. [33] [34] [35] A multicentre, randomized, open-label trial is underway to assess whether the combination of OAC and clopidogrel reduces the risk of bleeding and is not inferior to triple therapy with respect to the prevention of thrombotic complications after PCI in patients on OAC. 36 
Limitations
There are several limitations to our observational study. Data were not available regarding the degree of anticoagulation of these patients upon presentation, particularly when considering that subtherapeutic INR levels have been reported in 22-43% of patients on OAC. 37, 38 It is possible that part of the complex decision making for these patients would be affected by the INR levels, and this may have played a role in selection bias. We could not assess the impact of transradial versus transfemoral access on bleeding complications in the Cath/PCI group. It is also possible that certain characteristics and outcomes may not have been detected because of our sample size. Nonetheless, this is the largest study to date to explore the outcomes of STEMI patients on chronic OAC and the only one to portray the practice patterns with respect to this challenging patient population. Although propensity matching was performed for OAC and non-OAC patients, it is unlikely that our propensity-matched patients randomly received, or did not receive, chronic OAC. Thus, no inference should be made attributing chronic warfarin use in itself to better or worse outcomes. Secondly, because the propensity model was unusually discriminant (c-statistic of 0.92), few patients are left with similar propensities, implying the propensity-matched results pertain to a small subset of patients.
Conclusions
This group of patients has a high comorbidity burden, and the choice and timing of reperfusion and adjunctive therapies were based on clinical judgment. Despite apparent unadjusted differences between OAC users and non-users, the following propensity matching rates of in-hospital major bleeding or death and 6-month death were similar between the two groups. When comparing outcomes in STEMI patients on chronic OAC treated with medical therapy with those who received Cath/PCI, the latter were less likely to die in hospital or by 6 months post-discharge. While these observations could reflect adequate patient selection by the treating physicians, they should be interpreted with caution given their limited power and non-randomized nature and because unmeasured variables may have influenced the treatment choice. Furthermore, there are no randomized data to suggest whether a better treatment strategy actually exists. Bleeding complications also appear to be more frequent among STEMI patients on chronic OAC undergoing Cath/ PCI. Certainly, more data are required to better treat this intriguing patient population.
Conflict of interest
Sanofi-Aventis had no involvement in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. The design, conduct, and Table 7 . Selected landmark antiplatelet, anticoagulant, interventional, or STEMI management trials excluding patients on OAC.
Study
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